About
Optogenetic therapy for the Treatment of Atrial Fibrillation with an Implantable Optic
OptoRhythm is developing a novel light-based method for controlling heart rhythms. Built on over 20 years of research by Prof. Lior Gepstein, a leader in cardiac electrophysiology and optogenetics, OptoRhythm’s approach aims to improve treatment for Atrial Fibrillation (AF). The technology integrates optogenetic gene therapy with an implantable micro-LED array to create the first Optic Defibrillator, designed to stop chaotic atrial contractions through targeted light pulses, offering an alternative to traditional electric shocks. This real-time, repeatable, and non-destructive approach addresses limitations in existing AF treatments, aiming for sustained rhythm control and improved patient outcomes.
Identity
| Name | Optorhythm |
|---|---|
| Slug | optorhythm |
| Type / kind | startup |
| Source _id | sVoPWMSmNSCIDIAxlayGtZKoBbZtLujzlXl6uvRnzDrNLbHhiYvorF |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jul 2025 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country | Israel |
|---|---|
| HQ country code | IL |
| HQ address | Israel |
Web & social
| https://www.linkedin.com/company/105463860 |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}